The goal is then to license promising candidates to other pharmaceutical companies for advanced clinical development and commercialization...Pharmalink AB, of Stockholm, Sweden, inked an exclusive global license to the TARGIT drug delivery technology developed by Archimedes Pharma Ltd., of Reading, UK, for its lead program, Nefecon, in the treatment of the kidney disease IgA nephropathy

The goal is to combine DSM's drug delivery expertise with AdeTherapeutics' therapeutic and clinical development work...Horizon Pharma Inc., of Deerfield, Ill., said the FDA accepted the filing and will review its new drug application for Lodotra, a modified delayed-release formulation of low-dose prednisone, to treat rheumatoid arthritis in adults

Atlab Pharma SAS, of Nantes, France, and BZL Biologics LLC, of New York, entered a sublicense agreement to develop (177)Lu-J591 as a prostate cancer treatment...In addition to advancing a pipeline, Repligen runs a bioprocessing business through which it supplies technologies and ingredients used to manufacture biologics

Mitsubishi Tanabe Pharma Corp., of Osaka, Japan, received approval for the manufacturing and marketing of Telavic (telaprevir) in Japan to treat chronic hepatitis C. Mitsubishi licensed Japanese and Chinese rights to the drug from Cambridge, Mass.-based Vertex Pharmaceutical Inc., which markets it in the U.S...The program will use to-BBB's drug delivery technology to get NeuroVive's cyclosporin A therapy across the blood-brain barrier

BioAlliance Pharma SA, of Paris, said the company filed an appeal to the French Supreme Court on a procedural matter in arbitral proceedings it had initiated against SpePharm Holding BV, of Amsterdam, the Netherlands, and SpeBio BV, which the two companies formed as a joint venture to commercialize Loramyc in Europe (excluding France) under a 2007 agreement...Amarantus will pay a license fee of $10 million to Generex in Amarantus common stock valued at not less than $5 million and a three-year

The study suggested the protein could be combined with other blood tests to accurately capture at least 87 percent of patients with RA...Clavis Pharma ASA, of Oslo, Norway, was awarded a grant from The Research Council of Norway of up to $2.5 million for the development of a flow cytometry method to detect and quantify human equilibrative nucleoside transporter in patients with acute myeloid leukemia (AML

Acceleron Pharma Inc., of Cambridge, Mass., presented preclinical data showing RAP-661 increased bone mineral density, increased osteoblast activity and decreased osteoclast activity in a mouse model of bone loss...Aegis will apply its Intravail drug delivery technology to allow oral delivery of the peptide...Simcere also announced plans to purchase the land use rights in a Beijing innovation park for a regional R&D center

Nectid Inc., of Princeton, N.J., completed the sale of several patents and patent applications to Grunenthal GmbH, of Aachen, Germany, including a number of chemical pain drug entities and two drug delivery platforms...Zealand Pharma A/S, of Copenhagen, and Pepscan Holding NV, of Lelylstad, the Netherlands, jointly received an EU research and development grant of €860,000 (US$1,221,329) for the development of dual-acting peptide drugs

ERYtech Pharma Inc., of Lyon, France, completed enrollment and safety follow-up in a Phase II trial of GRASPA (encapsulated L-asparaginase in red blood cells) in first-line acute lymphoblastic leukemia in patients older than 55...package insert to allow patients to be treated on a dosing interval for up to eight weeks, which could reduce the number of injections required

Prior to the acquisition, the experimental drug had been in Phase II development...It will continue to pursue a global licensing strategy for the drug...Spencer Pharmaceuticals Inc., of Boston, signed a deal with Polyvalor LP, the commercial partner of Ecole Polytechnique de Montreal, to further develop the technologies related to efficient delivery of nucleic acids using chitosan, as well as for an innovative discovery of therapeutic nanocomplexes for Type II diabetes treatment and other possible

The acquired business, which includes all but the drug delivery technologies portion, has been renamed Corden Pharma Switzerland LLC and will operate as part of ICIG's pharmaceutical business within the Corden Pharma group...As part of the agreement, Corden Pharma contracted with Genzyme to provide materials needed for the production of eliglustat tartrate, an investigational treatment for Gaucher disease Type 1 that's in Phase III trials, and for the manufacture of other treatments

In other news, Elan and Celgene Corp., of Summit, N.J., entered a settlement and license agreement resolving a patent infringement suit involving breast cancer treatment Abraxane...In other news, Intercell and partner Biological E. Ltd., of Hyderabad, India, started a pediatric Phase II/III trial of a vaccine designed to protect children from Japanese encephalitis...In other news, Neovacs reported results from a Phase I/II study showing that its TNF-Kinoid was found to be safe in 21 patients with

AspenBio Pharma Inc., of Castle Rock, Colo., has been given an additional 180-day extension to remain listed on the Nasdaq Capital Market and regain compliance with the exchange's $1 minimum bid price rule...Ltd., of Seoul, South Korea, and Enlyton Ltd., of Columbus, Ohio, entered a licensing agreement that grants Enlyton exclusive worldwide rights to develop 3E8, a humanized monoclonal antibody designed to target the tumor-associated glycoprotein 72 antigen, for use in cancer detection and

In other news, Diamyd said its Phase III European Union study of antigen-based therapy Diamyd completed the 15-month visit...UCB SA, of Brussels, Belgium, said affiliate UCB Pharma SA and PDL BioPharma Inc., of Incline Village, Nev., entered into a settlement agreement that resolves all legal disputes between the companies, including those relating to UCB's pegylated humanized antibody fragment Cimzia (certolizumab pegol) and PDL's Queen et al...PDL agreed not to sue UCB for any royalties regarding

A.P. Pharma Inc., of Redwood City, Calif., said it arranged Type B meetings with the FDA later this quarter to address the complete response letter for APF530 for the prevention of chemotherapy-induced nausea and vomiting...Protect still retains the patents related to abuse-deterrent and once-daily gastro-retentive drug delivery platforms

Emisphere Technologies Inc., of Cedar Knolls, N.J., inked its second oral diabetes drug delivery deal with Copenhagen, Denmark-based Novo Nordisk A/S. Under the current deal, Emisphere will receive $5 million up front and a potential $52.5 million in milestones to use its Eligen technology to develop oral formulations of Novo's insulin products...is EpiCept's partner in Israel and, upon approval of labeling and other technical matters, the company is expected to launch the therapy in the first

Clavis Pharma ASA, of Oslo, Norway, said the FDA granted fast-track status to elacytarabine, which is in Phase III trials for late-stage acute myeloid leukemia...Drug delivery specialist Lipoxen plc, of London, announced positive Phase II results for its long-acting erythropoietin (EPO) ErepoXen...The product uses PolyXen drug-delivery technology to improve the efficacy, stability and half-life of protein drugs and reduces risk of toxicity

In January 2010, the companies announced a research collaboration and license agreement worth up to $1.4 billion for the research, development and commercialization of DsiRNA pharmaceuticals and drug delivery systems for therapeutic targets in oncology...Otherwise, the license leaves Stellar free to commercialize the technology, exclusively, in all other fields, according to Stellar

KGaA, of Bad Homburg, Germany, to create renal pharmaceutical company Vifor-Fresenius Medical Care Renal Pharma Ltd...Merrion Pharmaceuticals plc, of Dublin, Ireland, signed a deal with an undisclosed pharmaceutical company to evaluate whether Merrion's GIPET drug delivery technology can boost the bioavailability of three of the pharma's drugs...Following the feasibility study, the pharma will have an option to license the technology